CN1348003A - Hirudin gene hv 2-47k and its synthesis and expression - Google Patents
Hirudin gene hv 2-47k and its synthesis and expression Download PDFInfo
- Publication number
- CN1348003A CN1348003A CN 00129747 CN00129747A CN1348003A CN 1348003 A CN1348003 A CN 1348003A CN 00129747 CN00129747 CN 00129747 CN 00129747 A CN00129747 A CN 00129747A CN 1348003 A CN1348003 A CN 1348003A
- Authority
- CN
- China
- Prior art keywords
- hirudin
- gene
- novel
- asn
- pcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010007267 Hirudins Proteins 0.000 title claims abstract description 16
- 230000014509 gene expression Effects 0.000 title claims abstract description 16
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 33
- 229940006607 hirudin Drugs 0.000 claims abstract description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 19
- 150000001413 amino acids Chemical group 0.000 claims abstract description 11
- 108020004705 Codon Proteins 0.000 claims abstract description 7
- 241000235058 Komagataella pastoris Species 0.000 claims abstract description 5
- 230000002068 genetic effect Effects 0.000 claims abstract description 5
- 241000235648 Pichia Species 0.000 claims description 17
- 239000013604 expression vector Substances 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- QGNXYDHVERJIAY-ACZMJKKPSA-N Asn-Gln-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N QGNXYDHVERJIAY-ACZMJKKPSA-N 0.000 claims 1
- IICZCLFBILYRCU-WHFBIAKZSA-N Asn-Gly-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IICZCLFBILYRCU-WHFBIAKZSA-N 0.000 claims 1
- DYBIDOHFRRUMLW-CIUDSAMLSA-N Cys-Leu-Cys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)CS)C(=O)N[C@@H](CS)C(O)=O DYBIDOHFRRUMLW-CIUDSAMLSA-N 0.000 claims 1
- AAOBFSKXAVIORT-GUBZILKMSA-N Gln-Asn-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O AAOBFSKXAVIORT-GUBZILKMSA-N 0.000 claims 1
- RAUDKMVXNOWDLS-WDSKDSINSA-N Glu-Gly-Ser Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O RAUDKMVXNOWDLS-WDSKDSINSA-N 0.000 claims 1
- HPJLZFTUUJKWAJ-JHEQGTHGSA-N Glu-Gly-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HPJLZFTUUJKWAJ-JHEQGTHGSA-N 0.000 claims 1
- DGTOKVBDZXJHNZ-WZLNRYEVSA-N Ile-Thr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N DGTOKVBDZXJHNZ-WZLNRYEVSA-N 0.000 claims 1
- VGPCJSXPPOQPBK-YUMQZZPRSA-N Leu-Gly-Ser Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O VGPCJSXPPOQPBK-YUMQZZPRSA-N 0.000 claims 1
- SFQPJNQDUUYCLA-BJDJZHNGSA-N Lys-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)N SFQPJNQDUUYCLA-BJDJZHNGSA-N 0.000 claims 1
- QZONCCHVHCOBSK-YUMQZZPRSA-N Lys-Gly-Asn Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O QZONCCHVHCOBSK-YUMQZZPRSA-N 0.000 claims 1
- KYYMILWEGJYPQZ-IHRRRGAJSA-N Phe-Glu-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 KYYMILWEGJYPQZ-IHRRRGAJSA-N 0.000 claims 1
- RJHJPZQOMKCSTP-CIUDSAMLSA-N Ser-His-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(O)=O RJHJPZQOMKCSTP-CIUDSAMLSA-N 0.000 claims 1
- NLJKZUGAIIRWJN-LKXGYXEUSA-N Thr-Asp-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O NLJKZUGAIIRWJN-LKXGYXEUSA-N 0.000 claims 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 claims 1
- YQYFYUSYEDNLSD-YEPSODPASA-N Val-Thr-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O YQYFYUSYEDNLSD-YEPSODPASA-N 0.000 claims 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 claims 1
- 102000007625 Hirudins Human genes 0.000 abstract description 7
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract description 7
- 230000028327 secretion Effects 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000000855 fermentation Methods 0.000 abstract description 3
- 230000004151 fermentation Effects 0.000 abstract description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 abstract description 2
- 239000006228 supernatant Substances 0.000 abstract description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 229960001230 asparagine Drugs 0.000 abstract 1
- 235000009582 asparagine Nutrition 0.000 abstract 1
- 108010010968 hirudin HV2 Proteins 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- FIBJDTSHOUXTKV-BRHMIFOHSA-N lepirudin Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)CNC2=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1)C(C)C)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O FIBJDTSHOUXTKV-BRHMIFOHSA-N 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100036826 Aldehyde oxidase Human genes 0.000 description 2
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 2
- 206010051055 Deep vein thrombosis Diseases 0.000 description 2
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 2
- 101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 108010073652 desirudin Proteins 0.000 description 2
- 238000006477 desulfuration reaction Methods 0.000 description 2
- 230000023556 desulfurization Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229960004408 lepirudin Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229940030915 refludan Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 241000237902 Hirudo medicinalis Species 0.000 description 1
- 101150045458 KEX2 gene Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical group CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000296 desirudin Drugs 0.000 description 1
- XYWBJDRHGNULKG-OUMQNGNKSA-N desirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 XYWBJDRHGNULKG-OUMQNGNKSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000001723 fibrinogenic effect Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 108010002230 lepirudin Proteins 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 235000012976 tarts Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Based on the amino acid sequence data of over twenty natural hirudin mutants and by using HV2 hirudin as prototype, novel hurudin gene hv2-47k capable of inserting pPIC9 vector is finally obtained through replacing the asparagine (N) with lysine (K), selecting methanol yeast Picha pastoris preferred genetic codon, synthesizing eight-section deoxynucleotide segment (primer) and recursive PCR splice. The gene hv2-47k is expressed in secretion mode in methanol yeast Pichia pastoris, and in cylinder fermentation, the novel hirudin expression amount in the fermented supernatant liquid is not lower than 30000 ATU/ml (after inducement for 50 hr) or 2.0 g/L yield.
Description
The present invention relates to a kind of reconstituted drug, particularly hirudin gene and synthetic and expression thereof.
R-hirudin (Hirudin) is to separate a class polypeptide that obtains from Hirudo japonica (Hirudomedicinalis) sialisterium the earliest.Afterwards, the investigator separates the r-hirudin varient that obtains as many as 20 kinds from various bloodthirsty leech, they mostly are made up of more than 60 (64-69 is not waited) amino-acid residues, wherein maximum three kinds of varients (HirudinVariants) of being made up of 65 or 66 amino acid are used in research, be called HV1, HV2 and HV3, all natural hirudin C-hold all sulphatings (RobertHand, et al Transgenica-Topics in Clinical Biotechnology http://pharminfo.com/pubs/transgen/th-hir.html) of the 63rd tyrosine Tyr (Y).
R-hirudin all has very high avidity to people and other mammiferous zymoplasms, is the strongest zymoplasm natural inhibitor of finding so far.It is in conjunction with the center irreversible combination to take place by catalytic center and Fibrinogen with zymoplasm, makes the zymoplasm inactivation.R-hirudin of a part and the zymoplasm of a part form firm, non-covalent mixture, and therefore, the zymoplasm of inactivation is irreversible basically, and this just makes the hematoblastic activation process of fibrinogenic conversion and thrombin-mediated be blocked.
The N-end (1~39) of r-hirudin mainly contains hydrophobic amino acid, stablize by three intrachain disulfide bonds, and C-end (40~65) is rich in tart amino acid, and wherein the peptide section of 10 amino-acid residues compositions of C-end is specificity bind thrombin and the critical area that makes it inactivation.47 Methionins (K) residue to HV1 and HV3 discovers that K is to the active of r-hirudin and with the interaction of zymoplasm also very important (Mao, S.J.T., etal., Anal.Biochem.161:514-518,1987; Harvey, R.P., etal., PNAS (USA) 83:1084-1088,1986; Dodt, J., etal., FEBSLett.2 29:87-90,1988).The three-dimensional structure that 47 Methionins of HV2 may influence r-hirudin simultaneously by hydrogen bond and electrostatic interaction with and with the combination of zymoplasm, its thermostability is increased, biological activity improves 61% (Chinese biological chemistry and molecular biology journal such as Lu Yu peak, 1998; 14 (1): 32-37)
Limited in view of the natural hirudin source, in the later stage eighties, all begin one's study both at home and abroad and adopt genetic engineering technique to produce lepirudin 023 ludon, to satisfy the needs of pharmacology and clinical study test.The company that is engaged at present hirudin gene engineering research exploitation abroad is as many as 11 families.Wherein German Hoechst company holds primary Isoleucine (I) to become leucine (L) N of HV2, the 2 63 the tyrosine Tyr desulfurization r-hirudin Lepirudin (chemical name of producing: Leu1, Thr2-63-desulfohirudin, trade(brand)name REFLUDAN), its powder injection successively went on the market in the Europe and the U.S. in 1998, be used for the treatment of the thrombocytopenia (HIT, Heparin-induced thrombocytopenia) that heparin brings out.The 63rd the desulfurization r-hirudin that the Ciba-Geigy of Switzerland (NOVARTIS) company adopts recombinant technology to express in cereuisiae fermentum, called after Desirudin, trade(brand)name Revasc, be mainly used in the complication after bone surgery and other major operations, as dvt (DVT, Deep vein thrombo-sis) and pulmonary infarction (PE, Pulmonary embo lism), existing in Europe listing (Aventis-Refludan Prescribing Information http://www.Aventispharma-s.com/Pis/refludan-TXT.html).
Through after the analysis-by-synthesis, I am based on the aminoacid sequence of HV2, simultaneously with reference to HV1, the sequence of HV3,47 the l-asparagine (N) of HV2 is substituted by Methionin (K), the genetic codon of selecting for use methanol yeast Pichia pastoris to be liked, 8 sections oligonucleotide chains of synthetic (primer) (chain length 31-46 base does not wait), adopt recursion PCR (Recursive PCR) (Bi Qun, Huang Yixiu, the recurrence PCR of Zhu's hirudin gene in holy heptan synthetic and expression in intestinal bacteria and secretion Peking University's journal (natural science edition) 33 (6): 737-742,1997), splice novel this gene of r-hirudin hv2-47K and it is inserted among the Pichia yeast secretion type expression carrier pPIC9 construction of expression vector PIC8.2.Transform the Pichia yeast with this carrier, obtain the engineering bacteria that efficiently expresses.To the effect that of the present invention: 1.hv2-47k gene synthetic
According to the HV2-47K aminoacid sequence of design, consider the expression vector that will use, determine after the analysis of machine Autocad that as calculated full length gene is 222bp.We synthesize 8 oligonucleotide fragment/primers altogether to obtain this gene.For guaranteeing that the HV2 gene produces minimum assorted band through recursion PCR, every primer is with about 15 base pairs of adjacent primer strand complementary cohesive end.Because the carrier of selecting Pichia yeast secretion type expression carrier pPIC9 to insert as gene, so 5 '-ends in HV2-47K structure gene are designed the XhoI restriction enzyme site, and hold the codon that inserts KEX2 protease recognition sequence (K-R) between first amino-acid residue at this site and HV2-47K N-, so that target protein can successfully cut signal peptide when secretion; 3 '-end is TAA terminator codon and EcoRI restriction enzyme site (Fig. 1).Like this after the gene splicing success, through XhoI with EcoRI is two cuts, just can be inserted into the pPIC9 expression vector, construction of expression vector PIC8.2 (Fig. 3).2.hv2-47k Gene Sequence Analysis
The pPIC9 plasmid vector is a kind of shuttle vectors of Invitrogen company design, its plasmid that can increase in bacterium, the goal gene of integrating in yeast, inserting.This carrier has three sequencing primers: two target gene 5s '-the end primer (5 '-AOX1,2-Factor Seq) and one 3 '-the end primer (3 '-AOX1).Therefore; the structure of screening, order-checking and expression vector once can be finished; because the hv2-47k goal gene has only 222bp long; be inserted between the multiple clone site XhoI-EcoRI of pPIC9; so we select 5 for use '-the AOX1 primer is to goal gene in the pPIC9 expression plasmid check order (measure in last sea base health (Genecore) company, sequencer address is seen Fig. 2).By the result of order-checking as seen, the base sequence of goal gene does not go wrong when recurrence PCR splice, its 5 '-the XhoI point of contact of end, the base sequence of KEX2 enzyme recognition sequence (K-R), 3 '-end TAA termination codon and EcoRI restriction enzyme site be all with original design identical.In addition, from 3 '-end EcoRI site extend back AVrII, NotI restriction enzyme site the multiple clone site (MCS) of visible pPIC9.3.hv2-47k expression of gene
Express novel r-hirudin HV2-47K with the GS115-HV2-47K Pichia Yeast engineering bacteria that methanol induction makes up, adopt antithrombin vigor assay excretory r-hirudin amount (being the ATU of anti-freezing unit) to determine its expression level.Because the hv2-47k gene is a genetic codon of selecting for use methanol yeast Pichia pastoris to be liked, when shake-flask culture, hv2-47k gene expression amount in Pichia zymic nutrient solution supernatant is not less than 2,000ATU/ml (inducing 50 hours); When the 30L fermentation cylinder for fermentation, expression amount is not less than 30, and 000ATU/ml (inducing 50 hours) is equivalent to the output of 2.0g/L.
Synthetic eight sections few nucleic acid (primer) of embodiment 1:hv2-47k gene all synthesize in Shanghai bio-engineering corporation (Sangon), reclaim through the PAGE electrophoresis, are packed as the 10D/ pipe, synthetic numbering: 33502~33509, number certainly: P1~P8, in September, 97).The synoptic diagram of eight sections primer splicings is as follows:
For avoiding the phase mutual interference between the primer, earlier P3, P4, P5 and P6 are mixed and carry out first round PCR reaction, obtain one section of the centre of hv2-47k gene, be primer with P2, P7 again, first round PCR product is that template is carried out second and taken turns PCR, obtain the part broad in the middle of hv2-47k gene, taking turns the PCR product with second at last is template, is that primer splices complete hv2-47k gene with P1, P8.
3 PCR reactions of whole splicing experience can be finished, and PCR process and condition are as follows: PCR reaction (PCR-1) for the first time: 20ul reaction system: 0.3ul ... P40.3ul ... P52ul ... P32ul ... P61ul ... Mix-d NTP (every kind of dNTP contains 5mM) 2ul ... 10xTaq-plus damping fluid 1ul ... it is 20ul to cumulative volume that Taq-plus enzyme (cushioning, be diluted to 1u/ul with lxTaq-plus) adds ultrapure water 11.4ul.PCR reaction (PCR-2) for the second time: 20ul reaction system: 4ul ... PCR-1 reaction product 2ul ... P22ul ... P71ul ... Mix-d NTP (every kind of dNTP contains 5mM) 2ul ... 10xTaq-plus damping fluid 1ul ... Taq-plus enzyme (cushioning, be diluted to 1u/ul) with lxTaq-plus
Adding ultrapure water 8.0ul is 20ul to cumulative volume.PCR reaction (PCR-3) for the third time: 100ul reaction system: 5ul ... PCR-2 reaction product 4ul ... P14ul ... P83ul ... Mixed-dNTP (every kind of dNTP contains 5mM) 10ul ... Taq-plus damping fluid 1ul ... Taq-plus enzyme (proenzyme dress liquid, the suitable 5u of 1ul)
Adding ultrapure water 73ul is 100ul to cumulative volume.The reaction parameter setting of PCR: PCR-1, PCR-2 all take turns at 94 ℃, 60S/58 ℃, 70S/72 ℃, 70S circulation 30, finish rear electrophoresis at every turn and inspect, and determine that specificity is good, and when having only a band, just negate answers product to make the template of next round PCR.Since our design draw the complimentary piece segment length, whenever do not produce assorted band when taking turns PCR, thereby last round of PCR product can use as template directly.PCR-3 takes turns at 94 ℃, 60S/58 ℃, 70S/72 ℃, 70S circulation 30, and 72 ℃ were extended 6 minutes.Each step PCR product of whole recurrence PCR in 1.2% agarose gel electrophoresis result as shown in Figure 4.The structure of embodiment 2:hv2-47k expression vector PIC8.2 adopts the post absorption method to collect the target gene fragment that amplifies the PCR-3 product, cuts with XhoI-EcoRI is two, and glue reclaims and connects usefulness; Get the pPIC9 plasmid, cut with XhoI-EcoRI is two equally, glue reclaims big fragment and connects and use carrier.Set up following ligation system: 7ul ... hv2-47k gene 1ul after the recovery ... pPIC9 carrier 1ul after the recovery ... 10XT4 dna ligase 0.5ul ... T4 dna ligase (about 3U) 0.5ul ... dH2010ul ... total reaction volume is the condition of ligation: 22 ℃, 60 minutes, 65 ℃, 10 minutes.Ligation liquid is transformed E coli TOP10F ' competent cell born of the same parents with the Calcium Chloride Method preparation, and method is referring to J.Sambrook etal, Molecular Cloning a laboratory Mannual, and 2nded 1989.Bacterium after the conversion is layered on the LB+Amp plate, choosing positive colony from the LB+Amp flat board cultivates, extract plasmid, with XhoI, the screening of EcoRI double digestion method, the energy enzyme cuts out about 220 (216) bp band persons and is the PIC9 plasmid that is inserted in the hv2-47k gene, with 5 '-(Invitrogen Kit provides the AOX1 primer, or the sequence that provides by Kit is synthetic) to objective gene sequencing, the result shows: recurrence PCR splices the sequence requirement that the hv2-47k gene conforms with design fully, and is special with expression plasmid called after PIC8.2.Structure gene nucleotide sequence such as Fig. 2 of hv2-47k, building process as shown in Figure 3.Embodiment 3: the GS115-HV2-47K Pichia Yeast engineering bacteria 1 of structure). and Ecoli Top10F ' bacterium that preparation conversion Pichia zymic expression vector PIC8.2 plasmid will contain the PIC8.2 plasmid is in the LB+Amp+Kan liquid culture, with alkali extraction process large quantity extracting plasmid.The PIC8.2 plasmid linearization is made to transform the usefulness of Pichia yeast host bacterium GS115 with SalI.2) the .Pichia zymic transforms with linearizing PIC8.2 expression vector dna transformed competence colibacillus Pichia yeast GS115His
--Mut
+Host bacterium (competence adopts the Pichia Easy CompTransformation Kit preparation of Invitrogen company), press Pichia Expression Kit-ProteinExpression, Catalog No:K1710-01) described in step transform and screen.Because of host GS115 is His
-(histidine defect type), can not the MD plate on growth (1.34%YNB, 4 * 10
-5%Biotin, 2%Dextrose 1.5%Agar), has only the successful transformant of conversion to grow.3) screening of .GS115-HV2-47K Pichia Yeast engineering bacteria is chosen single bacterium colony from the MD plate, be inoculated into and contain 10mlYPD substratum (1%Yeast extract, 2%Peptone, 2%Dextose), cultivated 30 hours for 30 ℃, under the condition of aseptic technique, it is that 50ml shakes in the bottle that the collection thalline forwards the volume that contains 10mlMM inducing culture liquid to, be not less than 300 rev/mins of cultivations down, and, getting a sample and detect hirudin activity every 10 hours.Adding anhydrous methanol after each sampling is 0.5-1.0% to final concentration.The about 60-70 of inducing culture hour.High expression level amount (when hirudin activity is the highest) occurred between 55-65 hour.Constant relatively for guaranteeing the nutrient solution volume, take out how many samples at every turn, just add the MM nutrient solution of respective volume, other adds about 0.5ml distilled water and replenishes the water that evaporates.Finally obtain the Pichia Yeast engineering bacteria that to express HV2-47K, called after GS115-HV2-47KPichia yeast.Curve is as shown in Figure 5 over time for the expression amount of HV2-47K.
The r-hirudin hv2-47k gene base sequence and the aminoacid sequence of description of drawings: Fig. 1 design
5 '-hold to be restriction enzyme XhoI recognition sequence CTCGAG, and KEX2 protease recognition sequence amino acid correspondence
Codon AAAAGA; 3 '-hold sequencing result into terminator codon TAA and limiting enzyme EcoRI recognition sequence GAATTC Fig. 2 recurrence PCR method splicing hv2-47k
This figure has only intercepted the key component of former sequencer address, and wherein the fragment between XhoI point of contact and the EcoRI point of contact promptly
It is the agarose gel electrophoresis of three step of the process synoptic diagram Fig. 4 recurrence PCR method pcr amplification product of hv2-47k gene fragment Fig. 3 construction of expression vector PIC8.2
PCR-1: first round PCR product
PCR-2: second takes turns the PCR product
PCR-3: third round PCR product promptly obtains final hv2-47k gene
100bp Ladder
+Be dna molecular amount standard map 5 r-hirudin HV2-47k expression amount curve over time in Pichia pastoris
Wen Zhongyong capitalization roman HV2-47k represents the r-hirudin albumen that engineering bacteria is expressed, and represents hirudin gene with small letter italic hv2-47k.
Claims (4)
1. the novel r-hirudin HV2-47K of genetically engineered drug is characterized by, and this medicine is a genetic code of selecting for use methanol yeast Pichia pastoris to be liked, and the gene hv2-47k of synthetic expresses in the Pichia yeast and gets;
2. novel hirudin gene hv2-47k according to claim 1 and amino acid sequence coded thereof are as follows: CTC GAG AAA AGA ATT ACT TAC ACT GAT TGT ACA GAA TCG
Ile Thr Tyr Thr Asp Cys Thr Glu SerGGT CAA AAT TTG TGC CTC TGC GAG GGA AGC AAT GTT TGCGly Gln Asn Leu Cys Leu Cys Glu Gly Ser Asn Val CysGGT AAA GGC AAT AAG TGC ATA TTG GGT TCT AAT GGA AAGGly Lys Gly Asn Lys Cys Ile Leu Gly Ser Asn Gly LysGGC AAC CAA TGT GTC ACT GGC GAA GGT ACA CCG AAG CCTGly Asn Gln Cys Val Thr Gly Glu Gly Thr Pro Lys ProGAA AGC CAT AAC AAC GGC GAT TTC GAA GAA ATT CCA GAAGlu Ser His Asn Asn Gly Asp Phe Glu Glu Ile Pro GluGAA TAT TTA CAA TAA GAA TTCGlu Tyr Leu Gln
3. novel hirudin gene hv2-47k according to claim 1 can insert different expression vectors, selects eucaryon or procaryotic cell expression host to express, and does not insert the pPIC9 carrier and be not only limited to, and is transformed into and expresses in the Pichia yeast;
4. novel hirudin gene sequence according to claim 2 and aminoacid sequence thereof, the genetic code of every seed amino acid can be selected the different degenerate codons of the primary structure that does not influence novel r-hirudin HV2-47K for use, and is not limited only to the codon that the Pichia yeast is liked.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00129747 CN1348003A (en) | 2000-10-10 | 2000-10-10 | Hirudin gene hv 2-47k and its synthesis and expression |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 00129747 CN1348003A (en) | 2000-10-10 | 2000-10-10 | Hirudin gene hv 2-47k and its synthesis and expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1348003A true CN1348003A (en) | 2002-05-08 |
Family
ID=4593708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 00129747 Pending CN1348003A (en) | 2000-10-10 | 2000-10-10 | Hirudin gene hv 2-47k and its synthesis and expression |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1348003A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328380C (en) * | 2001-09-24 | 2007-07-25 | 天津天士力制药股份有限公司 | High-efficiency expression recombinant hirudin and producing method thereof |
CN102191264A (en) * | 2011-04-02 | 2011-09-21 | 江苏省中医药研究院 | Production method of recombined hirudin |
-
2000
- 2000-10-10 CN CN 00129747 patent/CN1348003A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1328380C (en) * | 2001-09-24 | 2007-07-25 | 天津天士力制药股份有限公司 | High-efficiency expression recombinant hirudin and producing method thereof |
CN102191264A (en) * | 2011-04-02 | 2011-09-21 | 江苏省中医药研究院 | Production method of recombined hirudin |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1240940A (en) | A-factor and its processing signals | |
EP0637630A2 (en) | Method for the biological synthesis of peptides | |
EP0020147B2 (en) | A dna transfer vector for human pre-growth hormone, a microorganism transformed thereby, and a method of cloning therefor | |
CN113444167A (en) | Recombinant human collagen polypeptide and application thereof | |
AU590238B2 (en) | Recombinant methods for production of serine protease inhibitors and dna sequences useful for same | |
CN1138856C (en) | Epidermal growth factor engineering bacteria and method for preparing epidermal growth factor using the bacteria | |
CN110724187B (en) | Recombinant engineering bacterium for efficiently expressing liraglutide precursor and application thereof | |
KR101026526B1 (en) | How E. coli secrete foreign proteins | |
CN108840951A (en) | A kind of fusion protein and preparation method thereof being made of pig albumin, Porcine interferon-gamma and porcine interferon alpha | |
ATE542913T1 (en) | PROMOTOR VARIANTS FOR EXPRESSING GENES IN A FUNGAL CELL | |
Ohmachi et al. | Molecular organization of developmentally regulated Dictyostelium discoideum ubiquitin cDNAs | |
CN108840938A (en) | A kind of fusion protein being made of pig albumin and Porcine interferon-gamma and preparation method thereof and a kind of Recombinant Swine long-acting interferon γ | |
CN1348003A (en) | Hirudin gene hv 2-47k and its synthesis and expression | |
Clary et al. | A cluster of six tRNA genes in Drosophila mitochondrial DNA that includes a gene for an unusual tRNAserAGY | |
CN108794638A (en) | A kind of recombinant bovine long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon | |
Wildeman | A putative ancestral actin gene present in a thermophilic eukaryote: novel combination of intron positions | |
CN101173003A (en) | Agkistrodon venom prothrombin activator, its coding sequence and use | |
CN101134963A (en) | Cascade expression method of recombinant human glandulae parathyroideae (1 to 34 peptide) | |
CN108840934B (en) | Recombinant sheep long-acting interferon tau, fusion protein for preparing long-acting interferon tau and preparation method of fusion protein | |
AU2002345249A1 (en) | Identification and cloning of the receptor gene for symbiotic nitrogen fixation | |
CN108840935A (en) | A kind of fusion protein being made of sheep albumin and sheep interferon gamma and preparation method thereof and a kind of recombination sheep long-acting interferon γ | |
CN116083401B (en) | Cas enzymes and systems and uses | |
CN108794637A (en) | A kind of canine recombinant long-acting interferon α and the fusion protein and preparation method thereof for preparing this long-acting interferon | |
Prasad et al. | A Plasmodium yoelii yoelii erythrocyte binding protein that uses Duffy binding-like domain for invasion: a rodent model for studying erythrocyte invasion | |
CN107365390A (en) | A kind of fusion protein being made up of pig albumin, Porcine interferon-gamma and pig interleukin 2 and 6 and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TANG DEJIANG Free format text: FORMER OWNER: MEI BOGAO Effective date: 20050610 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050610 Address after: 400020, building 8, building B, hung Cheng Building, Jianxin East Road, Jiangbei District, Chongqing Applicant after: Tang Dejiang Address before: 400041, 5 floor, biochemical garden, four street, 70 garden, Chongqing hi tech Zone Applicant before: Mei Bogao |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |